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Abstract
Background: Calprotectin is a calcium and zinc binding protein, abundant in neutrophils and is extremely stable
in faeces. Faecal calprotectin is used as a non-specific marker for gastrointestinal inflammation. It has a good
diagnostic precision to distinguish between irritable bowel syndrome and inflammatory bowel disease. Studies
have established normal concentrations in healthy children; all these studies have been performed in high-income
countries. The objective of this study was to determine the concentration of faecal calprotectin in apparently
healthy children aged 0-12 years in urban Kampala, Uganda.
Method: We tested 302 apparently healthy children aged, age 0-12 years (162 female, 140 male) in urban Kampala,
Uganda. The children were recruited consecutively by door-to-door visits. Faecal calprotectin was analyzed using a
quantitative enzyme-linked immunosorbent assay. Faeces were also tested for Helicobacter pylori (H. pylori) antigen,
for growth of enteropathogens and microscopy was performed to assess protozoa and helminths. A short
standardized interview with socio-demographic information and medical history was obtained to assess health
status of the children.
Results: In the different age groups the median faecal calprotectin concentrations were 249 mg/kg in 0 < 1 year
(n = 54), 75 mg/kg in 1 < 4 years (n = 89) and 28 mg/kg in 4 < 12 years (n = 159). There was no significant
difference in faecal calprotectin concentrations and education of female caretaker, wealth index, gender, habits of
using mosquito nets, being colonized with H. pylori or having other pathogens in the stool.
Conclusion: Concentrations of faecal calprotectin among healthy children, living in urban Ugandan, a low-income
country, are comparable to those in healthy children living in high-income countries. In children older than 4 years,
the faecal calprotectin concentration is low. In healthy infants faecal calprotectin is high. The suggested cut-off
concentrations in the literature can be used in apparently healthy Ugandan children. This finding also shows that
healthy children living under poor circumstances do not have a constant inflammation in the gut. We see an
opportunity to use this relatively inexpensive test for further understanding and investigations of gut inflammation
in children living in low-income countries.
Background
Calprotectin is a calcium and zinc binding heterocom-
plex protein, described by Fagerhol et al. in 1979 [1]. It
is abundantly present in the cytosol fraction of neutro-
phils [2], it is also found in monocytes/macrophages,
but is absent from platelets and lymphocytes [3]. It is
used as a non-specific marker for activation of granulo-
cytes and mononuclear phagocytes. Calprotectin is
remarkably resistant to degradation in the presence of
calcium, it is stable in faeces stored for 7 days at room
temperature [4] and no changes over time have been
found by storing the faeces at -20°C [5]. A faecal calpro-
tectin Enzyme-linked immunosorbent assay (ELISA) test
has been available since 1994 [6].
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Faecal calprotectin is used as a non-specific marker
for gastrointestinal (GI) inflammation. It has been
shown to correlate significantly with four day faecal
excretion of 111indium [7], the gold standard for intest-
inal inflammation. Faecal calprotectin concentrations are
elevated both in adults [4,8] and children [9-11] with
inflammatory bowel disease (IBD) and can be used to
evaluate the degree of inflammation in these patients.
For the diagnosis and more thorough investigation of
IBD, colonoscopy is needed. There is a significant corre-
lation between calprotectin concentration in gut lavage
fluid and intestinal permeability, suggesting that
increased intestinal permeability in IBD might be a con-
sequence of inflammation in the intestinal wall and
hereby increased transepithelial migration of neutrophils
[12]. Faecal calprotectin may differentiate between irrita-
ble bowel disease and IBD in school-age children [13].
Faecal calprotectin is found elevated in adults and chil-
dren with various GI infections [14-16], but the con-
centrations are lower than in persons with IBD.
Calprotectin is present in plasma, and the faecal calpro-
tectin concentrations might be increased with any bleed-
ing into the GI tract [17]. Elevated concentrations of
faecal calprotectin have been described in cystic fibrosis,
rheumatoid arthritis, Crohn’s disease, ulcerative colitis
and bacterial infection [6], as well as neoplastic condi-
tions [17] and Non-Steroidal Anti-Inflammatory Drugs
(NSAID) induced enteropathy [18]. In young infants
high faecal calprotectin concentrations are normal
[10,19]. In healthy pre-term babies the concentrations
are comparable with healthy term-babies [20,21], but in
very low birth weight babies (VLBW) developing severe
abdominal disease for instance necrotizing enterocolitis
(NEC), faecal calprotectin concentrations tend to
increase even more and it may be a marker for early
diagnosis [20,21].
Normal values for faecal calprotectin in different age
groups have been investigated in high-income countries
[10,20-22]. To our knowledge, there are no published arti-
cles on faecal calprotectin concentrations in apparently
healthy children living in low-income countries. In order
to even discuss the importance of calprotectin in low-
income countries, a baseline of healthy children has to be
done. A study on faecal calprotectin in Schistosomiasis
infected Ugandan children and adults have not shown an
increase of faecal calprotectin in the infected persons [23].
The objective of this study was to determine the con-
centration of faecal calprotectin in apparently healthy
children aged 0-12 years in urban Kampala, Uganda.
Methods
Study design, site and population
This is a cross-sectional survey in apparently healthy
children aged 0-12 years in urban Kampala, Uganda.
A detailed description is provided elsewhere [24]. Of the
472 children approached, 31 declined participation
(6.6%). Forty potential participants (9.1%) were excluded
from the final analysis due to positive human immuno-
deficiency virus (HIV) test (5), incomplete data (1),
failed to produce stool within two weeks (5) and medi-
cal conditions (29), figure 1. Within the group excluded
due to medical condition 23 reported to have ongoing
diarrhoea or diarrhoea within last two weeks, two had
congenital heart disease, one had a rectal prolapse, two
reported to have had nose bleeding within last two
weeks and one reported to have peptic ulcer. The
youngest child encountered in the survey was one week.
An additionally 99 stool samples were lost during trans-
port to the final laboratory. Children reporting chronic
cough/asthma were included as no studies have not
shown significant elevated concentrations of faecal cal-
protectin in children with asthma [25].
Data collection
The data collection took place October-November 2007
in Kampala, Uganda. All stool samples were investigated
by microscopy for protozoa and helminths, a culture
was performed to assess for enteropathogens and all
samples were tested for Helicobacter pylori (H. pylori)
with a rapid faecal monoclonal antigen test [24]. In
order to assess the faecal calprotectin concentrations
among healthy, non-HIV-infected, children in this high
Kawempe Division,
22% of Kampala’s population
Mulago II Parish,
1 of 22 parishes at Kawempe
472 children age 0<12 years 
consecutively approached
401 apparently healthy children 
age 0<12 years
40 children excluded:  
• medical conditions (29)
• positive HIV test (5)
• failed to provide stools (5)
• incomplete data (1)
441 available children
31 declined participation
302 samples for 
faecal calprotectin analysis
99 samples lost in transport
Figure 1 Study profile
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endemic area, all participants and their caretakers were
offered a voluntary HIV test.
Stool sampling and CALPRO® Calprotectin ELISA Test
A stool sample was requested from each participating
child. All participants were instructed from the data col-
lectors to pass stool on a newspaper that was handed
out and thereafter the stool was collected with the
spoon following the air tight containers either at time of
the encounter, at the end of the day, or the following
morning. All participants who had not delivered a stool
sample were visited once daily for the next two weeks.
A participant was included in the survey if he/she pro-
duced a stool sample within two weeks after the initial
interview. Stool samples were transported at ambient
temperature from the field to the laboratory twice daily
and stored in a +4°C fridge until the same afternoon or
the following day when a stool portion was frozen in a
clean Eppendorf tube at -80°C. The frozen stool samples
were transported on ice by air to Bergen where the final
analyses were performed in July 2009 using CALPRO®
Calprotectin ELISA Test (ALP). Instructions given by
the manufacturer were followed (http://www.calpro.no).
Eighty two of 302 faecal calprotectin samples (27%)
were measured twice to evaluate the consistency within
the pairs. In order to manage the data, all 164 concen-
trations were ranged into quartiles. The strength of
agreement, kappa (95%CI), was very good, 0.81 (0.70-
0.92). The CALPRO® Calprotectin ELISA Test (ALP) is
a quantitative method for the determination of calpro-
tectin in faeces. Calprotectin was expressed as milligram
per kilogram (mg/kg) of faeces. For children younger
than 4 years of age there are no reference limits estab-
lished for a positive test.
Statistical analysis
The statistical analysis were performed as described
elsewhere [24]. The data were exported to SPSS version
17.0 for statistical analysis. The concentration of faecal
calprotectin was expected to have a skewed distribution,
therefore the median was used. The confidence interval
(CI) reported was set to 95%. All tests were 2-sided,
p-value of 0.05 or less was considered significant. Faecal
calprotectin values in the different groups were com-
pared by using Mann-Whithey U test (for to different
groups) and by Kruskal-Wallis H test (for three or more
groups). Age was reported in mean and years.
Ethics
Ethical approval was obtained from Makerere University,
Faculty of Medicine, Research and Ethics Committee in
Uganda and the Regional Committee for Medical and
Health Research Ethics, West-Norway (REK-VEST) in
Norway. The data collectors were trained in ethical issues
prior to the study. Oral and written information about the
study was given to the caretakers either in English or the
local language. Informed consent was obtained from all
the caretaker of the participants in the study.
Results
The mean age (±SD) of all the participants was 4.9 (3.6)
years, for girls 5.4 (3.7) years and boys 4.4 (3.5) years. For
the children above 4 years the mean age (±SD) was 7.9
(2.2), for girls 8.0 (2.3) and boys 7.8 (2.2). Gender was
unequally represented in the study, 1) for all participants
162 (53.6%) girls and 140 (46.4%) boys, 2) for the children
above 4 years 96 (60.4%) girls and 63 (39.6%) boys.
The faecal calprotectin concentration had a skewed
distribution in the 302 apparently healthy children, fig-
ure 2. In the three age groups the number of children
were 54 (0 < 1 year), 89 (1 < 4 years) and 159 (4 < 12
years). The median faecal calprotectin concentrations
with 95% CI were 249 mg/kg (180-403) (0 < 1 year),
75 mg/kg (53-119) (1 < 4 years) and 28 mg/kg (25-35)
(4 < 12 years), table 1. There was a significant difference
in the faecal calprotectin concentrations across all three
age groups, regardless of gender. In the younger age
group the concentration of faecal calprotectin was more
spread and had a lager range than in the older children,
where the values were skewed towards the lower end of
the scale, figure 2. By dividing the children younger
than 1 year into 3 groups, 0 < 3 months (n = 14), 3 < 6
months (n = 13) and 6 < 12 months (n = 27) we found
that the youngest children had a trend for highest con-
centrations of faecal calprotectin (with 95%CI); 354
(195-621) (0 < 3 months), 278 (85-988) (3 < 6 months)
and 183 (109-418) (6 < 12 months), but none of this dif-
ferences were statistically different, table 1.
We performed a subgroup analysis of children aged
4 < 12 years where faecal calprotectin has proven to be
most useful and where reference values are available. By
performing Mann-Whithey U and Kruskal-Wallis H test
there was no significant relation between concentration
of faecal calprotectin and education of the female care-
taker, wealth index, sex, child using a mosquito net reg-
ularly, being colonized by H. pylori, Giardia intestinalis
(G.intestinalis) or other pathogens, table 2. Within the
last three months before inclusion 28.6% of the children
had been treated with antibiotics and 24.2% had been
treated for malaria; there were no significant difference
in median faecal calprotectin value in the treated versus
the not treated participants.
Of the 159 children above 4 years, 131 (82.4%) had
faecal calprotectin below 100 mg/kg, and 143 of the 159
children (89.9%) older than 4 years, had faecal calprotec-
tin below 150 mg/kg, table 3. Of the 28 children having
a faecal calprotectin higher than 100 mg/kg, 11 had an
intestinal infection with G. intestinalis and 1 had
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Ancylostoma duodenale. However, in 16 children we did
not find any explanation for faecal calprotectin over
100 mg/kg, the mean faecal calprotectin was 295 mg/kg
with a maximum of 895 mg/kg. Thirteen of the sixteen
were female, had a mean age (±SD) of 7.8 (2.3) years,
only three of them were using a mosquito bed net regu-
larly and ten were colonized with H. pylori.
Six participants reported themselves to be chronically
ill, five with chronic cough/asthma and one with head-
ache, all of them had a faecal calprotectin less than
40 mg/kg. In one culture only an enteric pathogen was
isolated; Campylobacter spp. The child was 10 years old
and the faecal calprotectin was 43 mg/kg.
The mean age (±SD) in the children whom stool was
lost in transport was 4.5 (3.7) years, with more boys
(58.6%) than girls (41.4%). Colonization rate with
H. pylori was 36.4%. The education of the female care-
taker, the practice of using mosquito net and the wealth
index were similar to the once completed the survey.
Discussion
This is the first survey of faecal calprotectin concentra-
tions in an apparently healthy population in Sub-
Saharan Africa. We have shown that cut-off values
recommended to use in children in high-income coun-
tries living in a relatively “clean environment” also are
valid in children in a low-income country. In our study
the median faecal calprotectin in apparently healthy
children older than 4 years was 28 mg/kg and within
the suggested cut-off concentrations for the test used.
By comparing our findings to other studies looking at
apparently healthy children, our median with 95% CI is
comparable to those studies [9,10,16,22,26,27].
Since none of the children with elevated faecal calpro-
tectin concentrations were followed up to see if the con-
centrations normalized over time, we do not have an
explanation for faecal calprotectin higher than 100 mg/kg
Outliers are designated
with a circle and extreme
outliers with a star.
***
***
*** There was a significant difference in the faecal calprotectin 
concentration across all three age groups, with a p-value< 0.001
Figure 2 Median faecal calprotectin with 95% CI by age in years
Table 1 Faecal calprotectin concentration in apparently
healthy children by age
Age Number (%) Median FC (mg/kg) (95%CI)
0 < 3 months 14 (4.6) 345 (195-621)
3 < 6 months 13 (4.3) 278 (85-988)
6 < 12 months 27 (8.9) 183 (109-418)
1 < 4 years 89 (29.5) 75 (53-119)*
4 < 12 years 159 (52.6) 28 (25-35) *
All 302 (100) 52 (40-73)
* Difference in median, p-value < 0.001 if compared with the whole group of
children younger than 12 months.
CI confidence interval
FC faecal calprotectin
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in 16 children. Spontaneous normalization in faecal cal-
protectin concentration without disease has been
described [22]. Use of NSAID is one common explana-
tion we did not control for [18]. The participants did not
go through a clinical examination and anal fissures with
bleeding or colon polyps as described in other studies
[28], could contribute to the increased concentration of
faecal calprotectin. We excluded all children reporting
diarrhoea within last two weeks before encountered in
the survey, but some few children could be carrier of
asymptomatic intestinal infection from pathogens we
have not examined for, for instance Cryptosporidia,
Some children with protozoa or helminths might have
been missed due to single sample investigation and with-
out additional tests. Ideally, identification of protozoa
and helminths are done using 3 consecutive stool sam-
ples [29,30]. A strength of our survey is that our children
were clinically healthy without diarrhoea and were HIV
negative. Another strength is that only one stool culture
was positive. Our study was preformed with the
improved faecal calprotectin assay, and it has been
argued that it gives a better separation between normal
and pathologic values [5]. We also adjusted for age within
the group of children age 4 < 12 years by applying bivari-
able linear regression (not shown), but we did not find
any changes.
There are few studies on faecal calprotectin and
GI-infections [15]. Colonization with G. intestinalis and
H. pylori are common in children living in Sub-Saharan
Africa [24,31,32]. In this survey we have found compar-
able colonization rates. Despite this the median faecal
calprotectin was within the recommended cut-off;
37.5 mg/kg for G. intestinalis and 33 mg/kg for
H. pylori. The findings in the G. intestinalis infected
group were comparable to a Norwegian study in adults
with chronic abdominal pain after G. intestinalis infec-
tion [14], where they found a median faecal calprotectin
concentration of 28 mg/kg in the G. intestinalis positive
Table 2 Faecal Calprotectin concentration in 159 apparently healthy children age 4 < 12 years
Number N (%) Median FC concentration (mg/kg) (95% CI) p-value
Sex
Female 96 (60.4) 27.5 (22-37) 0.94
Male 65 (39.6) 29 (24-38)
Education of female caretaker
Not completed secondary school 131 (82.4) 28 (24-35) 0.74
Completed secondary 28 (17.6) 28 (20-63)
Using a mosquito net
Yes 52 (32.7) 28 (21-35) 0.36
No 107 (67.3) 29 (24-40)
Wealth index
Poor 51 (32.1) 25 (20-34) 0.39
Poorer 55 (34.6) 30 (24-46)
Poorest 53 (33.3) 29 (22-40)
G.intestinalis seen by microscopy
Yes 35 (22.0) 40 (23-34) 0.12
No 124 (78.0) 27.5 (24-88)
H. pylori colonization
Yes 78 (49.1) 33 (25-46) 0.12
No 81 (50.9) 26 (22-34)
Other pathogens seen by microscopy ª
Yes 13 (8.2) 34 (18-46) 0.66
No 146 (91.8) 28 (23-35)
ª Campylobacter jejuni (1), Hymenolepis nana (5), Entamoeba histolytica (2), Ancylostoma duodenale (3), Ascaris lumbricoides (2)
N number
CI confidence interval
FC faecal calprotectin
Table 3 Distribution of the faecal calprotectin in
apparently healthy children >4 years
Faecal calprotectin
concentration (mg/kg)
Number
N
Percent
%
Cumulative
percent %
<50 111 69.8 69.8
50 < 100 20 12.6 82.4
100 < 150 12 7.5 89.9
≥150 16 10.1 100.0
Total 159 100.0 100.0
N Number
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patients. Colonization with H. pylori can cause changes
in the gastric mucosa [33], but there are no reports of
increased inflammation in the lower GI tract. Upper-GI
disorders have showed little increase in faecal calprotec-
tin levels [34]. Tibble et al. 2002 [35] found faecal cal-
protectin above the cut-off limit in participants infected
by G. intestinalis in their study, but those were sympto-
matic with diarrhoea.
Low-and middle-income countries are reporting an
increase in the incidence of IBD since the 1990’ties [36].
To the best of our knowledge there are no studies on the
prevalence of IBD in black children living in Sub-Saharan
Africa. In addition children living in low-income countries
have a higher burden of GI diseases including the effect of
HIV on the GI tract. This brings up the need for good
methods for improved diagnostics and awareness of GI
disorders. This study shows that apparently healthy chil-
dren do not have an ongoing inflammatory process in the
GI tract, and that methods used in high-income countries
with a lower burden of GI infection disease also are valid
in low-and middle-income countries. There is an ongoing
discussion on which upper limit, 100 mg/kg versus 50 mg/
kg, provides the best accuracy in diagnosing IBD [37]. For
the test we used, an upper limit of 50 mg/kg has been sug-
gested [5,38]. Tibble et al. 2000 used a cut-off concentra-
tion of 30 mg/l [7], which is equal to 150 mg/kg [5]. If we
use a cut-off of 100 mg/kg, 82.4% of the children had con-
centrations below, if we use 150 mg/kg, 89.9% of the chil-
dren had faecal calprotectin concentrations within that
range, table 3. A recently published meta-analysis con-
cludes that faecal calprotectin gives a diagnostic precision
in distinguishing IBD from non-IBD diagnosis, with higher
precision at a cut-off of 100 mg/kg versus 50 mg/kg [37].
Fagerberg et al [22] have documented that the same
cut-off limits used in adults are also applicable in chil-
dren older than 4 years. In infants and toddlers there
are no recommended cut-off values. In our study they
had higher faecal calprotectin concentrations than chil-
dren older than 4 years. The concentrations were com-
parable to those found in other studies of apparently
healthy children [10,27]. Our findings contribute to
establish reference values also for children younger than
4 years of age. We did not look at feeding practice in
children younger than 1 year. Studies diverge in the
conclusions if faecal calprotectin is higher in exclusively
breast feed children than in mix feed children [39,40].
There were no differences in median faecal calprotec-
tin according to sex [9,10,16], wealth index, health beha-
viour or education level of female caretaker. This is to
our knowledge demonstrated for the first time.
Conclusion
Apparently healthy Ugandan children, age 4 < 12 years,
have comparable concentrations of faecal calprotectin to
similar aged children in high-income countries. The
concentration of faecal calprotectin is high in Ugandan
children under 1 year of age, and is raised in toddlers.
Faecal calprotectin can be used in combination with
extended history and stool microscopy as a diagnostic
tool in children in need for further investigation for pro-
longed diarrhoea in a limited recourse setting. Faecal
calprotectin concentrations over 100 mg/kg in children
warrant follow-up. We see an opportunity to use this
relatively inexpensive test for further understanding and
investigations of gut inflammation in children living in
low-income countries.
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